ClinicalTrials.Veeva
Menu

Find clinical trials for Prostate Cancer in Toronto, ON

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Prostatic Cancer
Cancer
Carcinoma
Hypersensitivity
Recurrence
Adenocarcinoma
Breast Cancer

Prostate Cancer trials near Toronto, ON, CAN:

177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer

177Lu PSMA 617 is a new type of therapy which is designed to deliver high doses of radiation directly to prostate cancer sites in t ...

Active, not recruiting
Prostate Cancer
Drug: Docetaxel
Drug: 177Lu-PSMA-617

Phase 2

Canadian Cancer Trials Group

Toronto, Ontario, Canada and 9 other locations

androgen deprivation therapy (ADT) with a luteinising hormone releasing hormone analogue (LHRHA) in men having radiation therapy for localised prostate...

Active, not recruiting
Prostate Cancer
Drug: Placebo oral tablet
Drug: Luteinizing Hormone-Releasing Hormone Analog

Phase 3

University of Sydney

Toronto, Ontario, Canada and 92 other locations

Phase 1b study to assess the combination of ARV-110 and abiraterone in patients with metastatic prostate cancer with rising PSA val...

Active, not recruiting
Prostate Cancer Metastatic
Drug: ARV-110 in Combination with Abiraterone

Phase 1

Arvinas
Arvinas

Toronto, Ontario, Canada and 17 other locations

Laser Ablation (MRgFLA) in patients with early stage carcinoma of prostate. The results will be evaluated by repeated MRI and prostate...

Enrolling
Low and Intermediate Risk Prostate Cancer
Prostate Cancer
Device: The TRANBERGCLS|Thermal Therapy
University Health Network, Toronto
University Health Network, Toronto

Toronto, Ontario, Canada

Effects of Saruparib (AZD5305) Alone, Darolutamide Alone, and in Combination Given Prior to Radical Prostatectomy in Men with Newly Diagnosed Prostate...

Enrolling
Prostate Cancer
Drug: Saruparib (AZD5305)
Drug: Darolutamide

Phase 1

AstraZeneca
AstraZeneca

Toronto, Ontario, Canada and 16 other locations

ACCEL is a multicenter, open label phase Ia/Ib/II study of \[Ac-225\]-PSMA-62 in participants with prostate-specific membrane antigen (PSMA) ...

Enrolling
Hormone Sensitive Prostate Cancer
Metastatic Castration-resistant Prostate Cancer
Drug: [Ac-225]-PSMA-62 (mCRPC)
Drug: [Ac-225]-PSMA-62 (OmHSPC)

Phase 1

POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company

Toronto, Ontario, Canada and 1 other location

The purpose of this study is to find out what effects a new drug, palbociclib, has on prostate cancer and will look at the side eff...

Active, not recruiting
Prostate Cancer
Drug: Palbociclib

Phase 2

Canadian Cancer Trials Group

Toronto, Ontario, Canada and 6 other locations

and abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) who have received no prior cytotoxic chemo ...

Active, not recruiting
Metastatic Castration-resistant Prostate Cancer
Drug: abiraterone acetate
Drug: olaparib

Phase 3

AstraZeneca
AstraZeneca

Toronto, Ontario, Canada and 131 other locations

approach.Participants with high-risk prostate cancer planned for curative-intent standard-of-care radiotherapy or surgery, or with...

Active, not recruiting
Prostate Cancer
Other: Control Arm
Diagnostic Test: PSMA PET/CT guided intensification of therapy

Phase 3

Centre hospitalier de l'Université de Montréal (CHUM)

Toronto, Ontario, Canada and 18 other locations

hypo-fractionation (1.8-2.15Gy/fraction), both associated to an HDR prostate +/- adjacent seminal vesicles brachytherapy boost (HDR-BT)+ ADT...

Enrolling
Node; Prostate
Prostate Cancer
Radiation: Report and compare changes in a non-inferiority analysis of the International Prostate Symptom Score (I-PSS)
Radiation: Report and compare changes in a non-inferiority analysis of the expanded prostate cancer index composite" (EPIC-26):
Laval University

Mississauga, Ontario, Canada and 10 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems